13th Aug 2014 07:57
LONDON (Alliance News) - Hutchinson China MediTech Ltd said Wednesday that an independent data safety and monitoring committee had recommended that a Phase III trial of its HMPL-004 treatment for ulcerative colitis be terminated following an interim analysis of the trial.
The trial is being conducted by Nutrition Science Partners, Hutchinson's joint venture with Nestlé Health Science SA. The independent committee evaluated the data of two doses of the compound compared to a placebo. Hutchinson said that no meaningful safety signals or risks for patients were identified, and further analysis and review of the data will be conducted.
Nutrition Science Partners will continue to evaluate potential opportunities for the compound in "new indication areas and alternative regulatory pathways", Hutchinson said.
Shares in Hutchinson were trading down 7.6% at 979.15 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed